噬菌体展示
鉴定(生物学)
免疫球蛋白轻链
免疫系统
抗体
单域抗体
计算生物学
重链
生物
病毒学
链条(单位)
免疫学
物理
生态学
天文
作者
Ema Romão,Francisco Morales-Yánez,Yaozhong Hu,Maxine Crauwels,Pieter Pauw,Gholamreza Hassanzadeh,Nick Devoogdt,Chloé Ackaert,Cécile Vincke,Serge Muyldermans
标识
DOI:10.2174/1381612822666160923114417
摘要
Background: The discovery of functional heavy chain-only antibodies devoid of light chains in sera of camelids and sharks in the early nineties provided access to the generation of minimal-sized, single-domain, in vivo affinity-matured, recombinant antigenbinding fragments, also known as Nanobodies. Methods: Recombinant DNA technology and adaptation of phage display vectors form the basis to construct large naïve, synthetic or medium sized immune libraries from where multiple Nanobodies have been retrieved. Alternative selection methods (i.e. bacterial display, bacterial two-hybrid, Cis-display and ribosome display) have also been developed to identify Nanobodies. The antigen affinity, stability, expression yields and structural details of the Nanobodies have been determined by standard technology. Nanobodies were subsequently engineered for higher stability and affinity, to have a sequence closer to that of human immunoglobulin domains, or to add designed effector functions. Results: Antigen specific Nanobodies recognizing with high affinity their cognate antigen were retrieved from various libraries. High expression yields are obtained from microorganisms, even when expressed in the cytoplasm. The purified Nanobodies are shown to possess beneficial biochemical and biophysical properties. The crystal structure of Nanobody::antigen complexes reveal the preference of Nanobodies for cavities on the antigen surface. Conclusion: Thanks to the properties described above, Nanobodies became a highly valued and versatile tool for biomolecular research. Moreover, numerous diagnostic and therapeutic Nanobody-based applications have been developed in the past decade. Keywords: Cell biology tools, diagnostics, immune libraries, nanobodies, research tools, single domain antibodies, therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI